Safety and efficacy evaluation of albumin-bound paclitaxel

Sara Cecco, Maria Aliberti, Paolo Baldo, Elisa Giacomin, Roberto Leone

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe and the US; in combination therapy for non-small-cell lung cancer (NSCLC) and for first-line treatment of advanced pancreatic cancer (PC) only in the US. The European Medicines Agency has recently released only a positive opinion for use of nab-paclitaxel in PC. Areas covered: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. Expert opinion: In MBC, nab-paclitaxel has demonstrated a good safety and an efficacy profile compared with other taxanes, but no strong data on overall survival are available. Considering the role of markers or predictive factors for nab-paclitaxel effectiveness in the metastatic setting would be useful. In PC, nab-paclitaxel and gemcitabine represent a new therapeutic choice with significant improvement in survival. In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed.

Original languageEnglish
Pages (from-to)511-520
Number of pages10
JournalExpert Opinion on Drug Safety
Volume13
Issue number4
DOIs
Publication statusPublished - 2014

Fingerprint

Nanoparticles
Safety
Pancreatic Neoplasms
Non-Small Cell Lung Carcinoma
Breast Neoplasms
gemcitabine
Paclitaxel
Therapeutics
Taxoids
Survival
Expert Testimony
Albumin-Bound Paclitaxel
Histology

Keywords

  • Adverse drug reaction
  • Albumin-bound paclitaxel
  • Metastatic breast cancer
  • Pancreatic cancer
  • Squamous lung cancer

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Safety and efficacy evaluation of albumin-bound paclitaxel. / Cecco, Sara; Aliberti, Maria; Baldo, Paolo; Giacomin, Elisa; Leone, Roberto.

In: Expert Opinion on Drug Safety, Vol. 13, No. 4, 2014, p. 511-520.

Research output: Contribution to journalArticle

Cecco, Sara ; Aliberti, Maria ; Baldo, Paolo ; Giacomin, Elisa ; Leone, Roberto. / Safety and efficacy evaluation of albumin-bound paclitaxel. In: Expert Opinion on Drug Safety. 2014 ; Vol. 13, No. 4. pp. 511-520.
@article{857d5a170b1042a497ba7d2b3a356441,
title = "Safety and efficacy evaluation of albumin-bound paclitaxel",
abstract = "Introduction: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL{\circledR} vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe and the US; in combination therapy for non-small-cell lung cancer (NSCLC) and for first-line treatment of advanced pancreatic cancer (PC) only in the US. The European Medicines Agency has recently released only a positive opinion for use of nab-paclitaxel in PC. Areas covered: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. Expert opinion: In MBC, nab-paclitaxel has demonstrated a good safety and an efficacy profile compared with other taxanes, but no strong data on overall survival are available. Considering the role of markers or predictive factors for nab-paclitaxel effectiveness in the metastatic setting would be useful. In PC, nab-paclitaxel and gemcitabine represent a new therapeutic choice with significant improvement in survival. In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed.",
keywords = "Adverse drug reaction, Albumin-bound paclitaxel, Metastatic breast cancer, Pancreatic cancer, Squamous lung cancer",
author = "Sara Cecco and Maria Aliberti and Paolo Baldo and Elisa Giacomin and Roberto Leone",
year = "2014",
doi = "10.1517/14740338.2014.893293",
language = "English",
volume = "13",
pages = "511--520",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Safety and efficacy evaluation of albumin-bound paclitaxel

AU - Cecco, Sara

AU - Aliberti, Maria

AU - Baldo, Paolo

AU - Giacomin, Elisa

AU - Leone, Roberto

PY - 2014

Y1 - 2014

N2 - Introduction: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe and the US; in combination therapy for non-small-cell lung cancer (NSCLC) and for first-line treatment of advanced pancreatic cancer (PC) only in the US. The European Medicines Agency has recently released only a positive opinion for use of nab-paclitaxel in PC. Areas covered: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. Expert opinion: In MBC, nab-paclitaxel has demonstrated a good safety and an efficacy profile compared with other taxanes, but no strong data on overall survival are available. Considering the role of markers or predictive factors for nab-paclitaxel effectiveness in the metastatic setting would be useful. In PC, nab-paclitaxel and gemcitabine represent a new therapeutic choice with significant improvement in survival. In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed.

AB - Introduction: Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe and the US; in combination therapy for non-small-cell lung cancer (NSCLC) and for first-line treatment of advanced pancreatic cancer (PC) only in the US. The European Medicines Agency has recently released only a positive opinion for use of nab-paclitaxel in PC. Areas covered: This review reports the clinical findings and the safety data of nab-paclitaxel for MBC, NSCLC and PC. Expert opinion: In MBC, nab-paclitaxel has demonstrated a good safety and an efficacy profile compared with other taxanes, but no strong data on overall survival are available. Considering the role of markers or predictive factors for nab-paclitaxel effectiveness in the metastatic setting would be useful. In PC, nab-paclitaxel and gemcitabine represent a new therapeutic choice with significant improvement in survival. In a Phase III study with NSCLC patients, nab-paclitaxel showed better results in a subgroup of patients with squamous histology, for whom results with conventional therapies are still poor and improved therapeutic options are needed.

KW - Adverse drug reaction

KW - Albumin-bound paclitaxel

KW - Metastatic breast cancer

KW - Pancreatic cancer

KW - Squamous lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84899100191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899100191&partnerID=8YFLogxK

U2 - 10.1517/14740338.2014.893293

DO - 10.1517/14740338.2014.893293

M3 - Article

VL - 13

SP - 511

EP - 520

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 4

ER -